Therapeutic Potential of a Vasopressin V2 Receptor Antagonist for Calcium Channel Blocker-Associated Edema with Vasospastic Angina

Calcium channel blocker- (CCB-) associated peripheral edema does not resolve without CCB discontinuation or dose reduction. However, renin–angiotensin system (RAS) inhibitors have been reported to be effective for CCB-associated edema. We report a case of vasospastic angina with refractory CCB-assoc...

Full description

Saved in:
Bibliographic Details
Published inCase reports in cardiology Vol. 2022; pp. 1 - 5
Main Authors Toda, Kojiro, Fujino, Masashi, Murai, Kota, Noguchi, Teruo
Format Journal Article
LanguageEnglish
Published New York Hindawi 08.07.2022
Hindawi Limited
Wiley
Subjects
Angina pectoris
Antihypertensives
Blood pressure
Cardiac arrhythmia
Case Report
Case reports
Creatinine
Diuretics
Drug dosages
Edema
Electrocardiography
Electrolytes
Endocrine system
Enzymes
Hypertension
Kidney diseases
Laboratories
Peptides
Sodium
Online AccessGet full text

Cover

More Information
Summary:Calcium channel blocker- (CCB-) associated peripheral edema does not resolve without CCB discontinuation or dose reduction. However, renin–angiotensin system (RAS) inhibitors have been reported to be effective for CCB-associated edema. We report a case of vasospastic angina with refractory CCB-associated edema. A 78-year-old man had refractory edema induced by a CCB. It was successfully treated with tolvaptan, an active vasopressin V2 receptor antagonist. The aim of this case report is to understand the mechanism and treatment of CCB-associated peripheral edema and how tolvaptan affects peripheral edema.
Bibliography:Academic Editor: Manabu Shirotani
ISSN:2090-6404
2090-6412
DOI:10.1155/2022/9550006